转移性前列腺癌患者接受阿比特龙治疗期间肝功能指标升高的自然史、管理与结局
该研究回顾了2009年12月至2017年9月法国三个肿瘤中心25例转移性前列腺癌患者在接受阿比特龙治疗期间出现肝功能异常的事件。52%的患者在继续全剂量阿比特龙的情况下肝功自行恢复至基线。结论认为肝功指标升高是少见事件,多发生在治疗前两个月内,多数患者可自行恢复或经减量/停药后恢复。
要点
- 阿比特龙相关肝功升高多发生在治疗前2个月内,中位检出时间7.1周。
- 52%的患者在继续全剂量阿比特龙情况下肝功自行恢复至基线。
- 肝功升高后中位恢复至正常时间为6.2周。
核心结论
- 肝功指标升高是阿比特龙治疗中的少见事件,多发生在治疗前两个月内,多数患者可自行恢复或经减量/停药后恢复。
研究设计与样本
- 回顾性研究,纳入2009年12月至2017年9月法国三个肿瘤中心的25例转移性前列腺癌患者,这些患者在接受阿比特龙治疗期间出现肝功能检查异常。
主要发现
- ALT升高的患者中,1级、2级、3级分别为7例(32%)、6例(27%)、9例(41%);AST升高的患者中,1级、2级、3级分别为12例(50%)、6例(25%)、6例(25%)。
- 从开始阿比特龙至检出肝毒性的中位时间为7.1周(范围4-95周),从ALT/AST最高值至正常化的中位时间为6.2周(范围2-14周)。
- 13例患者(52%)在继续全剂量阿比特龙的情况下肝功自行恢复至基线值。
临床怎么用
- 接受阿比特龙治疗的患者应在治疗前两个月内密切监测肝功能,出现肝功升高时可考虑继续全剂量用药观察、减量或停药,多数患者肝功可恢复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abiraterone acetate (abiraterone) combined with prednisone is a standard of care in metastatic castration-resistant prostate cancer. Recently, benefit in overall survival was reported in metastatic castration-sensitive prostate cancer also, and an extension of indication has been granted. Abiraterone is seldom associated with liver toxicity. The clinical management and the outcome of patients with transaminase increase while on abiraterone have not been described. PATIENTS AND METHOD: We identified 25 men with metastatic prostate cancer and liver function test disorders occurring while on abiraterone treatment from December 2009 to September 2017 in three oncology centres in France. RESULTS: Forty-six liver disorder events occurred in 25 patients while on abiraterone treatment. The median age at liver function test increase was 67 (55-85) years. The incidence of aspartate aminotransférase (AST) (24 events) and that of alanine aminotransférase (ALT) (22 events) increases were similar. Liver toxicity was of grade 1, 2 and 3 (Common Terminology Criteria for Adverse Events. version 4) in 7 (32%), 6 (27%) and 9 (41%) patients for ALT, and in 12 (50%), 6 (25%) and 6 (25%) for AST, respectively. The median time from abiraterone initiation to the detection of liver toxicity was 7.1 (4-95) weeks. The median time from highest ALT/AST increase to normalisation was 6.2 [2-14] weeks. In 13 patients (52%), liver tests spontaneously returned to baseline values, while abiraterone was continued at full dose. CONCLUSION: Liver function test increase is a rare event that typically occurs within the first two months on abiraterone. Most patients experience normalisation of the tests, either spontaneously or after dose reduction/discontinuation.
引用
- Colomba E, Marret G, Baciarello G, et al. Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. Eur J Cancer. 2020. PMID: 32151941. doi:10.1016/j.ejca.2020.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。